- Home
- CEAD vs SLXN Comparison
CEAD vs SLXN Comparison
Compare CEAD & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEAD
- SLXN
- Stock Information
- Founded
- CEAD 2009
- SLXN 2008
- Country
- CEAD United States
- SLXN Israel
- Employees
- CEAD N/A
- SLXN N/A
- Industry
- CEAD Industrial Machinery/Components
- SLXN
- Sector
- CEAD Industrials
- SLXN
- Exchange
- CEAD Nasdaq
- SLXN NYSE
- Market Cap
- CEAD 6.4M
- SLXN 6.9M
- IPO Year
- CEAD N/A
- SLXN N/A
- Fundamental
- Price
- CEAD $7.78
- SLXN $0.93
- Analyst Decision
- CEAD
- SLXN Strong Buy
- Analyst Count
- CEAD 0
- SLXN 1
- Target Price
- CEAD N/A
- SLXN $5.00
- AVG Volume (30 Days)
- CEAD 6.8K
- SLXN 3.6M
- Earning Date
- CEAD 05-13-2025
- SLXN 05-21-2025
- Dividend Yield
- CEAD N/A
- SLXN N/A
- EPS Growth
- CEAD N/A
- SLXN N/A
- EPS
- CEAD N/A
- SLXN N/A
- Revenue
- CEAD $2,803,470.00
- SLXN N/A
- Revenue This Year
- CEAD N/A
- SLXN N/A
- Revenue Next Year
- CEAD N/A
- SLXN N/A
- P/E Ratio
- CEAD N/A
- SLXN N/A
- Revenue Growth
- CEAD N/A
- SLXN N/A
- 52 Week Low
- CEAD $5.60
- SLXN $0.21
- 52 Week High
- CEAD $12.26
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CEAD 42.56
- SLXN N/A
- Support Level
- CEAD $7.75
- SLXN N/A
- Resistance Level
- CEAD $8.77
- SLXN N/A
- Average True Range (ATR)
- CEAD 0.48
- SLXN 0.00
- MACD
- CEAD -0.05
- SLXN 0.00
- Stochastic Oscillator
- CEAD 6.15
- SLXN 0.00
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.